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Abstract 
Background 
Mitochondrial oxidative stress has a role in sepsis-induced organ dysfunction. The 
endogenous mechanisms to initiate protective pathways are controlled by peroxisome 
proliferator-activated receptor gamma co-activator 1-alpha (PGC1) and nuclear factor 
erythroid 2-like 2 (NFE2L2). Activation of these pathways are potential therapeutic 
targets in sepsis. We used pharmacological activators to determine the effects on 
markers of mitochondrial damage and inflammation in human endothelial cells under 
conditions of sepsis.  
Methods 
Human endothelial cells were exposed to lipopolysaccharide plus peptidoglycan G to 
mimic a sepsis environment, with a range of concentrations of a selective synthetic 
agonist of silent information regulator-1 (SIRT-1) which activates PGC1 or bis(2-
hydroxy-benzylidene) acetone (2HBA) which activates NFE2L2, with and without 
inhibitors of these pathways. Cells were cultured for up to 7d and we measured 
mitochondrial membrane potential and metabolic activity, and mitochondrial density as a 
marker of biogenesis, interkeukin-6 to reflect inflammation and glutathione as a 
measure of antioxidant status. 
Results  
Under conditions mimicking sepsis, activation of the PGC1and NFE2L2 pathways 
protected cells from LPS/PepG-induced loss of mitochondrial membrane potential 
(p=0.0002 and p=0.0009 respectively) and metabolic activity (p=0.05 and p<0.0001 
respectively) and dampened interleukin-6 responses (p=0.003 and p=0.0001 
respectively). Mitochondrial biogenesis (both p=0.0001) and glutathione (both 
p<0.0001) were also increased. These effects were blunted by the respective inhibitors. 
Conclusions 
The development of organ dysfunction during human sepsis is linked to mitochondrial 
dysfunction and so activation of PGC1/NFE2L2 is likely to be beneficial. These pathways 
are attractive therapeutic targets for sepsis. 
Sepsis is essentially a systemic, dysregulated and highly exaggerated inflammatory 
response to infection, accompanied by oxidative stress and mitochondrial dysfunction. In 
the developed world the incidence of sepsis continues to rise by around 10% annually 
and now claims more lives than breast and lung cancers combined. Mitochondria are the 
major physiological producers of reactive oxygen species (ROS) and during sepsis, 
mitochondrial ROS production exceeds antioxidant defences, leading to a state of 
oxidative stress which fuels inflammation and causes direct mitochondrial damage.1 The 
resulting mitochondrial dysfunction leads to further ROS release and initiates the same 
phenomenon, known as ROS-induced-ROS release, in neighbouring mitochondria. This 
self-perpetuating mechanism resulting in widespread mitochondrial dysfunction and 
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subsequent bioenergetic failure, is suggested to play a central role in sepsis-induced 
organ dysfunction2 3 and so therapeutic strategies to protect mitochondria during sepsis 
have been recognised as being important.3-5  
 
Peroxisome proliferator-activated receptor gamma (PPAR) co-activator 1-alpha (PGC1) 
is a co-activator of a number of transcription factors responsible for controlling cellular 
metabolism.6 7 Further transcription factors are under the control of PGC1, such as 
nuclear factor erythroid-derived 2-like-2 (NFE2L2)7 which regulates the expression of a 
number of protective mechanisms against oxidative stress, and GA binding protein 
transcription factor alpha (GABPA), which promotes activation of key transcription 
factors which control mitochondrial biogenesis. These events result in activation of 
protective cascades with generation of new mitochondria. A simple representation of  the 
key pathways and the points of action of the agonists and inhibitors used is provided in 
Figure 1. 
 
PGC1 is regulated at several levels including transcriptionally and post-translationally.6 8 
One of the various post-translational modifications which PGC-1 is capable of 
undergoing is deacetylation, catalysed by the enzyme silent information regulator-1 
(SIRT-1).8 As cellular energy levels decrease, SIRT-1 increases the activity of PGC-1 by 
removing acetyl groups. Under normal circumstances, SIRT-1 activity is regulated by the 
energy status of cells, but it can be also increased by synthetic agonists.9  
 
NFE2L2 is present constitutively in the cell cytoplasm bound to a repressor protein called 
Kelch-like ECH-associated protein 1 (KEAP-1), and activation occurs when oxidant 
species react with cysteine in the KEAP-1 molecule. This then allows translocation of 
NFE2L2 into the cell nucleus where it binds to antioxidant response elements (ARE) to 
induce upregulation of key antioxidant enzymes. Agonists which act on the repressor 
protein KEAP can be used to activate NFE2L2.10  
 
Activation of the PGC1NFE2L2 pathways are attractive potential therapeutic targets in 
sepsis and so the aim of this study was to pharmacologically activate the PGC1 and 
NFE2L2 pathways using two different agonists and to determine the effects of these 
interventions on markers of mitochondrial damage and inflammation in human 
endothelial cells under conditions which mimic sepsis. In addition the effect of inhibitors 
of these pathways were also studied. 
 
Materials and methods 
The agonists used in this study were 2-amino-N-cyclopentyl-1-(3-methoxypropyl)-1H-
pyrrolo [2,3-quinoxaline]–3-carboxamide also known as SIRT-1-activator-3, a selective 
synthetic agonist of SIRT-1 which increases deacetylation of PGC19 and bis(2-hydroxy-
benzylidene) acetone (2HBA) which is structurally related to curcumin10 and acts as an 
agonist of NFE2L2 via effects on the KEAP-1 repressor protein. In addition, inhibitors 
were used to block NFE2L2 and SIRT-1 activation: trigonelline hydrochloride11 and an 
indole derivative, 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide (EX527) 
respectively.12  
Cell studies 
All experiments were carried out using the human umbilical vein endothelial cell line, 
HUVEC-C (ATCC/LGC Standards Ltd., Middlesex, UK). Cells were cultured in Dulbecco's 
modified Eagle's medium (DMEM), containing 100mg L-1 glucose and without L-
glutamine (Invitrogen, Paisley, UK), and supplemented with 10% heat activated foetal 
calf serum, 50 g mL-1 gentamicin, and 250 μg mL-1 amphotericin B, at 37°C in a 
humidified atmosphere of 95% air and 5% carbon dioxide.13 For experimentation cells 
were cultured in the presence of 2 g mL-1 lipopolysaccharide (LPS, Escherichia coli 
0111:B7, Sigma-Aldrich Ltd., Poole, Dorset, UK) plus 20 g mL-1 peptidoglycan G 
(PepG), prepared as described previously,13 to simulate sepsis, plus a range of 
concentrations of either 2HBA, or SIRT 1-activator-3. In some experiments 20 μM 
trigonelline hydrochloride or 1μM EX527 were included. Some drugs were prepared 
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initially in ethanol to aid solubility, before diluting in DMEM to 1% (v/v). Control cells 
were treated with a vehicle control containing 1% ethanol where appropriate.  
Acid phosphatase activity 
Acid phosphatase activity was used to assess effects of agonists and inhibitors on cell 
viability.14 Cells were grown in 96-well plates and treated as described above for up to 
7d then washed twice with phosphate buffered saline (PBS). Acid phosphatase solution 
containing 0.1M sodium acetate, 1% v/v Triton X-100 and 5mM p-nitrophenyl in distilled 
water (pH 5.0) was added to each well and cells were incubated in the dark for 1h at 
37°C. Sodium hydroxide (0.25M) was added to stop the reaction and the absorbance 
measured. Viability was calculated relative to vehicle control treated cells. 
Interleukin-6 (IL-6) 
Accumulation of IL-6 in cell culture medium was used as a measure of the inflammatory 
response. Cells were grown in 96 well plates and incubated as above for 24h. IL-6 was 
measured in cell supernatants using enzyme immunoassay according to the 
manufacturer’s instructions (R&D Systems, Oxford, UK) and as we have previously 
reported.13 
Mitochondrial membrane potential  
Mitochondrial membrane potential was analyzed in intact cells using the fluorescent 
probe JC-1 (5,5,6,6-tetrachloro-1,1,3,3-tetraethylbenzimidazolcarbocyanine iodide, 
Invitrogen, Paisley, UK), a lipophilic cation which accumulates within the negatively 
charged matrix of intact energized mitochondria, as we have reported previously.13 JC-1 
fluoresces green in low concentrations, but at high concentrations forms so called ‘J-
aggregates’ which fluoresce red. Mitochondrial membrane potential is proportional to 
red/green fluorescence ratio.15 After 7d treatments as described above, cells were 
washed with PBS and then incubated for 30 min with JC-1 in PBS at 37oC, in the dark. 
Following incubation, cells were washed again with PBS and the red/green fluorescence 
ratio was measured immediately at 37oC. A decrease in the ratio of red/green 
fluorescence indicates loss of mitochondrial membrane potential.  
Metabolic activity  
Metabolic activity was analyzed by measuring the rate of reduction of AlamarBlue™ in 
intact cells after 7d treatment as above.16 Briefly, following cell treatments, 
AlamarBlue™ was added to each well and fluorescence was measured every 10 min for 2 
h at 37oC. Metabolic activity was determined as the rate of change in fluorescence over 
time at 37oC.  
Mitochondrial density  
MitoTracker green FM is a dye which localises to mitochondria independently of 
mitochondrial membrane potential and so can be used to determine mitochondrial 
density as a surrogate for the number of mitochondria and hence increases reflect 
biogenesis.17 Cells were grown in 96-well plates and treated as before for 7d. After 
incubation, cells were washed twice with PBS then 0.5µM MitoTracker Green FM 
(Invitrogen) in PBS was added and cells were incubated in the dark, for 30 min at 37°C.  
Excess dye was removed by washing with PBS then the fluorescence was measured at 
37oC. 
Total reduced glutathione  
Glutathione was measured as an indicator of mitochondrial antioxidant levels. The 
lipophilic compound monochlorobimane (Sigma-Aldrich) binds to glutathione via the 
action of the enzyme glutathione-S-transferase. The fluorescence of the resulting 
conjugate is proportional to the reduced glutathione concentration.18 Cells were treated 
for 7d as previously described, washed in PBS, then monochlorobimane solution added. 
After incubation at 37 oC in the dark for 15 min, glutathione levels were analysed by 
measuring fluorescence.   
Statistical analysis 
Six independent experiments with 4 technical replicates were undertaken (n=6). Data 
are presented as percentage of median control value without LPS to allow direct 
comparisons between cell treatments. No assumptions were made about data 
distribution and data are shown as median, interquartile and full range. Statistical 
analysis was undertaken on raw data, using Analyse-It Statistical Add-in for Microsoft 
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Excel. Comparisons between vehicle control and LPS/PepG treated cells without agonists 
and between cells treated with LPS/PepG plus agonist with and without the relevant 
inhibitor were undertaken using Wilcoxon-Mann Whitney testing. Effects of the different 
concentrations of the agonists on LPS/PepG treated cells was assessed initially using 
Kruskal Wallis analysis then Wilcoxon-Mann Whitney post hoc testing as appropriate.  A 
p value of <0.05 was taken as significant.  
 
Results 
Cell viability 
None of the concentrations of the agonists or the inhibitors had a detrimental effect on 
cell viability after 7d exposure with or without LPS/PepG at the concentrations used, 
although treatments above this range did have a marked effect on viability in the 
presence of LPS/PepG. Viability of cells was over 90% after 7d exposure to any of the 
treatments in all experiments. Full viability data are shown in the supplementary file. 
Interleukin-6 
IL-6 was significantly higher in culture supernatants after 24h treatment of endothelial 
cells with LPS/PepG compared to vehicle control cells, as expected (Figure 2). Treatment 
of cells with LPS/PepG plus SIRT-1-activator-3 resulted in significant suppression of 
LPS/PepG-induced IL-6 release (p=0.003, Figure 2A) with the most marked effect at the 
highest concentration. Inclusion of the inhibitor EX527 blunted the effect of SIRT-1 
activation on IL-6 concentrations (p=0.002, Figure 2A). Treatment of cells with 
LPS/PepG plus 2HBA resulted in markedly lower IL-6 at all concentrations of 2HBA such 
that levels were similar to control values at the highest concentration of 2HBA 
(p=<0.0001, Figure 2B). When cells were also exposed to trigonelline the IL-6 
concentration was significantly higher than without the inhibitor, but remained lower 
than with LPS/PepG alone (p=0.0007, Figure 2B). In the absence of LPS/PepG, basal IL-
6 levels were also significantly decreased by 2HBA but not SIRT-act-3 (see 
supplementary file). 
Mitochondrial assays 
Significantly lower mitochondrial membrane potential, metabolic activity and 
mitochondrial volume were seen in cells exposed to LPS/PepG for 7d compared to control 
cells (Figure 2A-2F). Treatment of cells with SIRT-1-activator-3 or 2HBA plus LPS/PepG 
resulted in restoration of membrane potential at the highest concentrations of both the 
agonists, and this effect was blocked by the relevant inhibitor (Figures 3A and 3D). The 
effect of SIRT-1 activator-3 on metabolic activity just failed to reach statistical 
significance (p=0.05) although co-treatment with the inhibitor resulted in significantly 
higher metabolic activity than with the agonist alone (p=0.0001, Figure 3B). In cells 
treated with LPS/PepG plus 2HBA, metabolic activity was significantly higher (p=0.0001, 
Figure 3E) such that at the highest concentrations of 2HBA, levels were similar to that of 
control cells. Again the inhibitor prevented this increase (p=0.0001, Figure 3E). 
Mitochondrial density was significantly increased in SIRT-1-activator-3 treated cells at 
the highest concentration only and there  was no significant effect of the inhibitor (Figure 
3C). In contrast, mitochondrial density was lower in those cells treated with LPS/PepG 
plus 2HBA (p=0.0001), an effect which was ameliorated by trigonelline (p=0.002, Figure 
3F). In the absence of LPS/PepG, SIRT-1-activator-3 had no effect on any mitochondrial 
assay, but metabolic activity was lower in the presence of EX527 alone (see 
supplementary file). 2HBA also did not affect any of the mitochondrial assays but 
trigonelline treatment alone resulted in higher mitochondrial metabolic activity and lower 
density (see supplementary file). 
Glutathione  
Seven days exposure to LPS/PepG had minor effects on endothelial cell glutathione 
levels (Figure 4A and 4B). Despite this, SIRT1-activator-3 had marked dose dependent 
effects on glutathione, resulting in large increases (p<0.0001, Figure 4A). This effect 
was partially blocked by the antagonist (p=0.0004, Figure 4A). In cells treated with 
LPS/PepG plus 2HBA, glutathione levels were modestly but significantly higher than with 
LPS/PepG alone only at the highest 2HBA concentration (Figure 4B) and co-treatment 
with inhibitor resulted in glutathione levels below that of the control cells (p<0.0001, 
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Figure 4B). Even in the absence of LPS/PepG a similar pattern of effect on glutathione by 
SIRT-1-activator-3 and EX527 was seen but neither 2HBA nor trigonelline had any effect 
(see supplementary file). 
 
Discussion 
In this study we showed that, under conditions mimicking sepsis, activation of the 
PGC1and NFE2L2 pathways using pharmacological approaches protected human 
endothelial cells from mitochondrial damage, and dampened the inflammatory response. 
Activation of NFE2L2 markedly suppressed LPS-PepG induced IL-6 responses, improved 
mitochondrial membrane permeability and metabolic activity, but did not promote 
mitochondrial biogenesis or increase glutathione levels. Activation of PGC1had minor 
yet significant effects on IL-6, but protected against loss of mitochondrial membrane 
potential and metabolic activity and resulted in increased mitochondrial density 
(biogenesis) in addition to markedly increasing glutathione levels. Inhibitors blunted 
these effects. These data show that activation of these interacting pathways impacts 
upon inflammatory responses and mitochondrial changes induced by an environment 
mimicking sepsis and may suggest future novel therapeutic targets. 
 
Some confusion has arisen in previous literature since the same alias (Nrf2) has been 
commonly used for both nuclear factor-erythroid-derived 2-like 2 (official abbreviation = 
NFE2L2) and GA binding protein transcription factor alpha (official abbreviation = 
GABPA, but also known as nuclear respiratory factor 2).19 It is now clear that PGC1 
participates in the signalling pathways of both these transcription factors, which are 
nevertheless distinct. PGC1co-activates both NFE2L2 and GABPA, notably under 
conditions of redox imbalance;20 NFE2L2 regulates the expression of antioxidant 
mechanisms, whilst GABPA promotes translocation of transcription factors into 
mitochondria which ultimately upregulate mitochondrial biogenesis (Figure 1). 
 
Oxidative stress, inflammation, antioxidant depletion and mitochondrial damage and 
dysfunction have been consistently described in sepsis1 3 21 22 and so restoration of 
endogenous antioxidant levels and preventing and/or restoring mitochondrial energetic 
function is likely to be beneficial in sepsis.3-5 In this context, the PGC1-NFE2L2 pathway 
has emerged as a potential target due to its control of mitochondrial biogenesis, 
metabolism, inflammatory mediators and endogenous antioxidants.6 In this study we 
pharmacologically activated SIRT-1 with SIRT-1-activator-3, a compound which has 
been shown to specifically interact with and activate SIRT1, but not other SIRT isoforms, 
resulting in deacetylation and activation of PGC1 whilst EX527 is a potent and 
selective inhibitor of SIRT1 activity.12 We used 2HBA to activate NFE2L2 via modifying its 
repressor KEAP-1,10 and trigonelline, which inhibits NFE2L2 by blocking its translocation 
into the nucleus.11   
 
Activation of NFE2L2 by 2HBA acts byt directly modifying cysteine sulphydryl groups in 
KEAP-1, causing a conformational change, allowing release and translocation of NFE2L2 
into the nucleus. This upregulates expression of targets with ARE in their upstream 
promotors and results in transcription of several protective pathways such as enzymes 
which control the synthesis and metabolism of glutathione (Figure 1).7 10 Thus 2HBA is 
an indirect inhibitor of the interaction between NFE2L2 and KEAP-1; such inhibitors can 
be grouped according to their structures and the way in which they interact with cysteine 
sulphydryl groups. So called ‘Michael acceptors’ are olefins or acetylenes conjugated with 
electron-withdrawing carbonyl groups and include both curcumin and 2HBA.23 24 
Trigonelline (N-methylnicotinic acid) is one of the major alkaloids in raw coffee beans, 
and has been shown to inhibit the nuclear translocation of NFE2L2.11 Treatment of cells 
with 2HBA plus trigonelline would therefore promote the dissociation of NFE2L2 from its 
repressor but translocation would be inhibited and NFE2L2 would be functionally inactive. 
 
Treatment of endothelial cells with LPS/PepG as used here has previously been shown to 
result in oxidative stress with alterations to mitochondria and consumption of 
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glutathione, along with inflammatory responses associated with activation of the 
transcription factor nuclear factor kappa B (NFB).13 25 We have also shown previously 
that antioxidants which specifically protect mitochondria ameliorate such LPS/PepG 
mediated effects both in vitro and in whole animal models.13 25 26 In this current study we 
used pharmacological agonists to promote the endogenous signalling mechanisms which 
protect and replenish damaged mitochondria. Activation of the PGC1-NFE2L2 pathway 
under conditions mimicking sepsis was able to ameliorate the reduction in mitochondrial 
membrane potential and metabolic activity mediated by LPS/PepG treatment in a similar 
way to exogenous antioxidants which act in mitochondria such as melatonin or mitoQ.13 
25 15 Indeed, melatonin may exert some of its protective effects via SIRT-1.27 
 
Reactive oxygen species produced by mitochondria (mtROS) may drive inflammatory 
cytokine production including IL-63 28 and early relative levels of IL-6 and the anti-
inflammatory cytokine IL-10 are important in terms of the severity of sepsis.29 Evidence 
of mitochondrial damage and dysfunction plus increased NFB activation and elevated 
biomarkers of inflammation are also seen in patients with sepsis.1 3-5 Previous studies 
have described a role for NFE2L2 signalling in down-regulation of inflammation19 30 and 
we showed here that activation of NFE2L2 by 2HBA had profound effects on IL-6, with 
almost complete suppression of the IL-6 response under conditions of sepsis, an effect 
also seen in cells without LPS/PepG. This is likely to be via effects on NFB since 
disruption of NFE2L2 signalling in knockout mice treated with LPS had enhanced NFB 
activation with increased inflammatory cytokine expression and higher mortality.30 
Others have also reported that PGC1 knockout mice have decreased NFE2L2 with 
increased levels of inflammatory cytokines.31 We found a definite dampening effect of 
PGC1 activation on IL-6 levels, but the effect was much less than that seen when 
NFE2L2 was activated.  IL-6 has important roles in various aspects of the immune 
response during sepsis and contributes to acute phase and inflammatory responses. High 
IL-6 concentrations have been shown previously to be associated with increased 
morbidity and mortality in sepsis.32 We have reported elevated IL-6 levels in conjunction 
with decreased antioxidant defences and biomarkers of oxidative stress and acute phase 
inflammation, in patients with sepsis.22 The agonist 2HBA, as well as facilitating nuclear 
translocation of NFE2L2, may also activate SIRT1 and/or cAMP response element binding 
protein (CREB), thus promoting activation of PGC1which then in turn co-activates 
NFE2L2; this may explain the large effects on IL-6.19 33 It is interesting that the complete 
reversal of the effect of 2HBA on the mitochondrial assays and glutathione by trigonelline 
was not reflected in the effect of trigonelline on IL-6. Although the 2HBA-mediated 
decrease in IL-6 release was not completely reversed by trigonelline, it is important to 
note the effect of the inhibitor did result in IL-6 levels above that seen with 2HBA alone 
with no overlap of the ranges, although still well below the level with LPS/PepG alone. 
IL-6 was measured after 24h since this is the time frame for the response to LPS/PepG 
exposure and this may impact on the difference between the effects of trigonelline on IL-
6 compared to other measures which were after 7d exposure to treatments. IL-6 is 
regulated mainly via NFB and we have assumed the effects of 2HBA on IL-6 are 
mediated by NFE2L2/NFB interactions. The effects of 2HBA on mitochondrial function 
are not regulated via NFB. 
 
We investigated the effect of activating the PGC1/NFE2L2 pathways on glutathione 
levels under conditions of sepsis. We did not find altered total cellular glutathione 
although we have previously found a decreased ratio of reduced:oxidised glutathione 
after 7d of LPS/PepG treatment using the same model, indicating consumption of 
reduced glutathione and oxidative stress.13 Strikingly however, treatment of cells with 
SIRT-1-activator-3 resulted in profound dose-dependent increases in  glutathione levels, 
which were decreased slightly by the EX527 inhibitor; similar effects were seen even in 
the absence of LPS/PepG. Treatment of cells with 2HBA plus LPS/PepG also resulted in 
increased glutathione levels, but the effects were much less marked than the effects of 
SIRT1 activation. Trigonelline reversed the effect of 2HBA on glutathione. We have 
shown previously that the oxidative stress induced by LPS/PepG in the endothelial cell 
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model used here results in mitochondrial oxidative stress.34 Superoxide generated inside 
mitochondria is primarily converted to hydrogen peroxide within the mitochondria by 
superoxide dismutase. The hydrogen peroxide formed is then removed mainly by 
oxidation and reduction of mitochondrial glutathione by the actions of mitochondrial 
glutathione peroxidase-1 and glutathione reductase. Oxidation of mitochondrial 
thioredoxin-2 (TRX-2) also has an important role in detoxifying hydrogen peroxide and 
we have shown previously in the same cell model that the TRX-2 system may be more 
important for protection against mitochondrial dysfunction induced by LPS/PepG than the 
glutathione system.34 Most glutathione is present in the reduced form (GSH) and the 
large increases seen in response to SIRT1 activation are likely to be due to increased 
synthesis. Synthesis of -L-glutamyl-L-cysteinyl-glycine, the tripeptide known as GSH, 
occurs in a two step process and it is the first step involving the enzyme glutamate–
cysteine ligase (GCL, previously known as γ-glutamylcysteine synthase), which is rate 
limiting. Expression of GCL has been shown to be controlled via NFE2L219 and so it was 
somewhat surprising to see that SIRT1-activator-3 had a much larger effect on 
glutathione than 2HBA. However it has been suggested that in addition to PGC1co-
activating NFE2L2, the converse is also true.19 In addition glutathione synthesis can also 
be affected by substrate availability and feedback inhibition.  
 
The production of structurally and functionally intact mitochondria occurs via biogenesis, 
a  process involving growth and division of existing mitochondria and requires the co-
ordinated response of both mitochondrial and nuclear transcription factors which direct 
transcription and replication of mitochondrial DNA. Only a small number of the proteins 
required for biogenesis are actually encoded by mitochondrial genes. In fact biogenesis 
requires the co-ordinated synthesis and importation of around a thousand proteins into 
the mitochondria, along with post-translational assembly processes in the mitochondrial 
membrane. In addition biogenesis also requires sequential fusion and fission processes.6 
The master regulator of this complex process is PGC1. Although biogenesis is a 
physiological process needed for replacement of damaged mitochondria and can be 
triggered by exercise, exposure to cold, and other environmental stressors, under 
conditions of inflammation including sepsis, biogenesis is crucial for production of 
adequate numbers of functionally intact mitochondria to cope with the increased energy 
demand. Studies in animals have shown that recovery after sepsis is associated with 
recovery of mitochondrial number and increased expression of PGC135 and animals 
genetically deficient in PGC1 did not mount this response.36 These PGC1+/- mice also 
had decreased nuclear NFE2L2 expression, confirming the role of PGC-1 as a co-
activator of NFE2L2.  
 
Here, we investigated the scenario of conditions of sepsis with oxidative stress but in the 
presence of pharmacological PGC1 or NFE2L2 activation. We found that only SIRT-1-
activator-3 (ie activation of PGC1) was able to promote biogenesis. This fits with the 
role of PGC1 in co-activation of GABPA which then promotes the activation pathways 
required for biogenesis to occur.6 19 However PGC1 activation is complex and can occur 
via a large number of routes, such as calcium and second messenger pathways, 
hormones, cyclin dependent kinases, energy dependent pathways and post-translational 
modifications including phosphorylation and deacetylation.6 EX527 did not have a full 
reversal effect on the increase in mitochondrial density in cells co-treated with LPS/PepG 
plus SIRT-1-activator-3. The action of EX527 has been shown to be via a unique NAD- 
dependent mechanism with partial formation of a product37 such that EX527 inhibits the 
action of the activator rather than PGC1 activation per se. It is possible to speculate 
that this may have some impact on our findings. Direction of cellular responses towards 
biogenesis, antioxidant mechanisms or anti-inflammatory responses is also likely to 
depend on the  exact mechanism of activation. The  decreased/increased biogenesis 
seen with 2HBA alone/2HBA plus trigonelline respectively suggests that direction of the 
cellular response pathways towards antioxidant/anti-inflammatory responses occurs in 
preference to biogenesis pathways when NFE2L2 is activated by 2HBA. Inclusion of 
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trigonelline prevents nuclear translocation of NFE2L2 but activation of PGC1by 2HBA 
may still occur. Our data suggest that dissection of the relative contribution of activation 
of PGC1 or NFE2L2 is complex, with reciprocal co-activation and engagement of 
multiple pathways as a result of exposure to the septic insult in addition to the 
pharmacological agonists. 
 
The development of organ dysfunction during human sepsis is linked to mitochondrial 
dysfunction and cellular energetic failure and so activation of PGC1/NFE2L2 is likely to 
be beneficial. Although genetic techniques such as the use of small interfering RNA 
(siRNA) can offer exact specificity, the pharmacological approach used here has perhaps 
more potential for translation to clinical use in the future. Other compounds which can 
activate the PGC1 pathway and have been given safely to humans include curcumin 
analogues, resveratrol and a synthetic SIRT-1 activator SRT2104.38  A mixed response to 
pre-treatment with oral SRT2104 in healthy men given a dose of LPS was recently 
reported, with dampening effects on IL-6 and IL-8 but no effect on clinical symptoms or 
markers of cell activation.39 However SRT2104 levels after oral dosing were variable and 
oral bioavailability of SRT2104 was low.38 39 Resveratrol has also been hampered by 
similar oral bioavailability issues although improvements using nanotechnology are 
encouraging.  
 
In summary we have shown that pharmacological activation of the PGC1and NFE2L2 
pathways in an endothelial cell model under conditions mimicking sepsis has protective 
effects on mitochondria, the glutathione system and IL-6. Although cell studies are only 
models for research purposes endothelial cells do have vital roles in host defence and 
inflammation during sepsis. Approaches which augment the body’s own endogenous 
responses to combat oxidative damage are likely to be the most promising treatment 
strategies for sepsis in the future and the PGC1-NFE2L2 pathway is a potential target. 
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Figures 
 
 
Figure 1 
Very simplified depiction of the pathways described in this paper. PGC1 can be 
regulated post-translationally via SIRT-activator-3 (1) and this is inhibited by EX527 
(2). Activation of PGC co-activates NFE2L2 (3), which can also be activated by 2HBA 
via actions on its repressor protein KEAP-1 (4). When activated, NFE2L2 translocates 
into the nucleus (5) and this can be blocked by trigonelline (6). In the nucleus NFE2L2 
activates ARE (7) which leads to upregulation of protective antioxidant pathways (8), 
and inhibits NFB (9). PGC also co-activates GABPA (10) leading to transcription of 
genes needed for biogenesis and synthesis of key mitochondrial proteins. There is 
also the suggestion that NFE2L2 may in turn activate PGC (12). For abbreviations 
see main text. Green traffic light indicates activator; red traffic light indicates 
inhibitor. 
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Figure 2 
Effect of A. activation of PGCby SIRT-1-activator-3 with and without and the 
inhibitor EX527 and B. activation of NFE2L2 by 2HBA with and without the inhibitor 
trigonelline, on IL-6 concentrations in culture medium from endothelial cells treated 
with LPS and PepG for 24h. Box and whisker plots show median, interquartile and full 
range as percentage of cells treated with vehicle control alone (n=6). P value in 
italics is Kruskal Wallis across LPS/PepG plus activator groups. Other p values are 
from Mann Whitney-Wilcoxon test. 
# = significantly lower than with LPS/PepG alone (p<0.05). 
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Figure 3 
Effect of activation of PGCby SIRT-1-activator-3 with and without the inhibitor 
EX527 on A. mitochondrial membrane potential B. mitochondrial metabolic activity C. 
mitochondrial volume. Effect of activation of NFE2L2 by 2HBA with and without the 
inhibitor trigonelline on D. mitochondrial membrane potential E. mitochondrial 
metabolic activity and F. mitochondrial volume, in intact endothelial cells treated with 
LPS and PepG for 7d.  
Box and whisker plots show median, interquartile and full range as percentage of 
cells treated with vehicle control alone (n=6). P value in italics is Kruskal Wallis 
across LPS/PepG plus activator groups. Other p values are from Mann Whitney-
Wilcoxon test. 
*= significantly higher and # = significantly lower than with LPS/PepG alone 
(p<0.05). 
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Figure 4 
Effect of A. activation of PGCby SIRT-1-activator-3 with and without the inhibitor 
EX527 and B. activation of NFE2L2 by 2HBA with and without the inhibitor trigonelline 
on glutathione (GSH) content in intact endothelial cells treated with LPS and PepG for 
7d. Box and whisker plots show median, interquartile and full range as percentage of 
cells treated with vehicle control alone (n=6). P value in italics is Kruskal Wallis 
across LPS/PepG plus activator groups. Other p values are from Mann Whitney-
Wilcoxon test.  *= significantly higher than with LPS/PepG alone (p<0.05). 
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